Egyptian Businessman Ayman Abbas Acquires 10% Stake in Proptech Platform Aqar Exit at $2M Valuation
The $200,000 capital injection by the Intro Holding executive chairman supports product development and Gulf market expansion ahead of a targeted $5M round in 2027.
CAIRO — Egyptian prominent businessman Ayman Mamdouh Abbas, Executive Chairman of Intro Holding Group, has acquired a 10% equity stake in Cairo-based proptech startup Aqar Exit.
The primary investment injects $200,000 (~EGP 10 million) into the company, valuing the real estate contract assignment platform at $2.0 million (~EGP 100 million) post-money. The transaction follows Aqar Exit’s feature on Shark Tank Egypt.
Marketplace Model & Platform Traction
Founded in July 2026 by Chief Executive Officer Dr. Mahmoud Ammar, Aqar Exit operates a digital marketplace designed to address installment defaults and illiquidity in Egypt’s primary residential market:
- Secondary Assignment Facilitation: Connects primary property buyers unable to maintain developer installment plans with prospective buyers seeking real estate without traditional resale markups or developer contract assignment fees.
- Price Parity Structure: Enables original buyers to exit obligations and recover paid capital while offering secondary buyers access to off-plan units at original developer contract pricing.
- Early Operational Metrics: The platform reported facilitating approximately EGP 9.0 billion (~$180 million) in aggregate secondary transaction interest and listings across its first two months of operations.
Use of Capital & Regional Growth Strategy
The seed tranche provides balance sheet runway for product diversification and cross-border expansion:
- Gulf Market Penetration: Capital will finance regulatory, technical, and commercial groundwork for expansion across key Gulf Cooperation Council (GCC) real estate markets.
- Product Pipeline: Supports the development of digitized escrow tools, automated developer compliance mechanisms, and asset verification protocols.
- Future Capitalization: Serves as a bridge toward a targeted $5.0 million Series A round planned for 2027, targeting regional venture funds and institutional real estate investors.
The Intelligence Engine for African Private Capital
Access complete transaction breakdowns, fund strategy updates, and market commentary directly on our platform.
Written by
Read next
Tactful AI Secures Pre-Series A Extension Investment from Former e& Group CEO Hatem Dowidar
The Cairo- and Cambridge-based agentic CX infrastructure platform expands its funding base following a $1M capital raise as it prepares for a planned 2027 Series A round.
Aries Media Ventures Launches Fund I for Sub-Saharan Media-Tech, Backs Initial Trio of Startups
The early-stage venture firm deploys capital from its inaugural fund into creator economy, events commerce, and venue booking platforms across Kenya, Ghana, Uganda, Rwanda, Tanzania, and South Africa.
Healthleap Secures $38M Seed & Series A to Expand EHR Clinical AI Platform
Co-founded by South African siblings Josiah and Jemima Meyer, the healthtech startup closes a major funding round from Sequoia Capital, First Round Capital, and Hummingbird Ventures to scale its hospital risk-detection software across US health systems.
UK Government’s FCDO Commits $15M via MOBILIST to Anchor Quickmart’s IPO
The UK public investment programme acquires 260 million shares in the Kenyan retailer, joining the International Finance Corporation to anchor the country’s largest retail public listing on the NSE.
ADvTECH Acquires 25% Stake in South African AI EdTech Startup MathU
The JSE-listed education and staffing group secures a board seat and exclusive rights to MathU's current and future AI-enhanced learning suite to scale personalised instruction across its African network.
Psyence BioMed Completes $2.6M Investment in PsyLabs Following Ibogaine Milestone Approvals
The Nasdaq-listed biotech exercises a $2.6 million backstop commitment to raise its stake in natural API developer PsyLabs to 43.37%, securing African-sourced pharmaceutical-grade ibogaine supply for U.S. clinical trials.